A CHIRALITY-DEPENDENT ACTION OF VITAMIN C IN SUPPRESSINGKIRSTEN RAT SARCOMA MUTANT TUMOR GROWTH BY THE OXIDATIVECOMBINATION: RATIONALE FOR CANCER THERAPEUTICS

Simple item page
dc.contributor.authorWu, Xinggang
dc.contributor.authorPark, Mikyung
dc.contributor.authorSarbassova, Dilara A.
dc.contributor.authorYing, Haoqiang
dc.contributor.authorLee, Min Gyu
dc.contributor.authorBhattacharya, Rajat
dc.contributor.authorEllis, Lee
dc.contributor.authorPeterson, Christine B.
dc.contributor.authorHung, Mien-Chie
dc.contributor.authorLin, Hui-Kuan
dc.contributor.authorBersimbaev, Rakhmetkazhi I.
dc.contributor.authorSong, Min Sup
dc.contributor.authorSarbassov, Dos D.
dc.date.accessioned2022-02-02T15:19:56Z
dc.date.available2022-02-02T15:19:56Z
dc.date.issued2019-08-31
dc.description.abstractKirsten rat sarcoma (KRAS) mutant cancers, which constitute the vast majority of pancreatic tumors, are characterized by their resistance to established therapies and high mortality rates. Here, we developed a novel and extremely effective combinational therapeutic approach to target KRAS mutant tumors through the generation of a cytotoxic oxidative stress. At high concentrations, vitamin C (VC) is known to provoke oxidative stress and selectively kill KRAS mutant cancer cells, although its effects are limited when it is given as monotherapy. We found that the combination of VC and the oxidizing drug arsenic trioxide (ATO) is an effective therapeutic treatment modality. Remarkably, its efficiency is dependent on chirality of VC as its enantiomer D-optical isomer of VC (D-VC) is significantly more potent than the natural L-optical isomer of VC. Thus, our results demonstrate that the oxidizing combination of ATO and D-VC is a promising approach for the treatment of KRAS mutant human cancersen_US
dc.identifier.citationWu, X., Park, M., Sarbassova, D. A., Ying, H., Lee, M. G., Bhattacharya, R., Ellis, L., Peterson, C. B., Hung, M., Lin, H., Bersimbaev, R. I., Song, M. S., & Sarbassov, D. D. (2020). A chirality‐dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. International Journal of Cancer, 146(10), 2822–2828. https://doi.org/10.1002/ijc.32658en_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/6016
dc.language.isoenen_US
dc.publisherInternational Journal of Canceren_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectKirsten rat sarcomaen_US
dc.titleA CHIRALITY-DEPENDENT ACTION OF VITAMIN C IN SUPPRESSINGKIRSTEN RAT SARCOMA MUTANT TUMOR GROWTH BY THE OXIDATIVECOMBINATION: RATIONALE FOR CANCER THERAPEUTICSen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Intl Journal of Cancer - 2019 - Wu - A chirality‐dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant.pdf
Size:
986.66 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Articles